A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-09-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. Cognitive enhancers help people afflicted with these conditions. However, some people do not benefit from this treatment, while others experience serious side effects. Side effects and poor response lead to hospitalization and early institutionalization. Pharmacogenomics, the study of how DNA variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with Lewy body disease. The goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. This can reduce health care costs and improve treatment to Canadians suffering from these devastating disorders.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

NCT00230997

Lewy Body Disease

COMPLETED PHASE3

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517

Mild Cognitive Impairment Mild Alzheimer Disease

RECRUITING EARLY_PHASE1

A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

NCT01807026

Alzheimer Disease Healthy Volunteers

COMPLETED PHASE1

Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects

NCT00366483

Alzheimer Disease

COMPLETED PHASE1

Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies

NCT05304195

Dementia With Lewy Bodies

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lewy Body Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's Disease Dementia

Participants in the Parkinson's Disease Dementia group:

* Must be taking a stable parkinsonian medication
* Must have a diagnosis of clinically definite Parkinson's disease \>1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.
* Response to cholinesterase inhibitor over a period of six months will be monitored.

Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)

Intervention Type DRUG

Dementia with Lewy Bodies

Participants in the Dementia with Lewy Bodies group:

* Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.
* Response to cholinesterase inhibitor over a period of six months will be monitored.